Evommune's CEO is Luis Pena, appointed in Apr 2020, has a tenure of 6.25 years. total yearly compensation is $11.02M, comprised of 5.3% salary and 94.7% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $6.46M. The average tenure of the management team and the board of directors is 4.1 years and 5.9 years respectively.
How has Luis Pena's remuneration changed compared to Evommune's earnings?
Date
Total Compensation
Salary
Company Earnings
Mar 31 2026
n/a
n/a
-US$76m
Dec 31 2025
US$11m
US$588k
-US$69m
Sep 30 2025
n/a
n/a
-US$63m
Jun 30 2025
n/a
n/a
-US$66m
Mar 31 2025
n/a
n/a
-US$80m
Dec 31 2024
US$7m
US$546k
-US$68m
Compensation vs Market: Luis's total compensation ($USD11.02M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Luis's compensation has increased whilst the company is unprofitable.
CEO
Luis Pena (63 yo)
6.3yrs
Tenure
US$11,022,670
Compensation
Mr. Luis C. Pena has been Founder, President, Chief Executive Officer and Director at Evommune Inc. since April 2020. He Co-founded Dermira Inc. in August 2010 and had been its Chief Development Officer si...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Luis Pena
Founder
6.3yrs
US$11.02m
1.36% $ 6.5m
Kyle Carver
Chief Financial Officer
4.3yrs
US$4.40m
0.014% $ 64.3k
Gregory Moss
Chief Business & Legal Officer
4.1yrs
US$4.60m
0.023% $ 107.9k
Eugene Bauer
Co-Founder
no data
no data
0.73% $ 3.5m
Jeegar Patel
Chief Scientific Officer
3.8yrs
no data
0.017% $ 78.8k
Janice Drew
Chief of Development Operations
less than a year
no data
0.11% $ 538.3k
Lou Sehl
Senior Vice President of Technical Operations
4.1yrs
no data
no data
Daniel Burge
Senior Vice President of Clinical Development
no data
no data
no data
J. Jackson
Senior Vice President of Clinical Development
less than a year
no data
no data
4.1yrs
Average Tenure
63yo
Average Age
Experienced Management: EVMN's management team is considered experienced (4.1 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Luis Pena
Founder
6.3yrs
US$11.02m
1.36% $ 6.5m
Eugene Bauer
Co-Founder
6.3yrs
no data
0.73% $ 3.5m
Arthur Kirsch
Independent Director
less than a year
US$451.24k
0.028% $ 132.1k
Benjamin McGraw
Independent Chairman of the Board
5.8yrs
US$490.83k
0% $ 0
Robert Hopfner
Independent Director
6yrs
no data
0.011% $ 53.2k
David Cohen
Independent Director
6.2yrs
US$484.58k
0.049% $ 232.6k
Felice Verduyn-Van Weegen
Independent Director
4.8yrs
no data
no data
Derek DiRocco
Independent Director
1.8yrs
no data
no data
5.9yrs
Average Tenure
62yo
Average Age
Experienced Board: EVMN's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/12 07:48
End of Day Share Price
2026/07/10 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evommune, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.